# Tesamorelin Side Effects and Safety Signals in the Research Literature > Tesamorelin side effects reported in trials center on injection-site reactions, fluid retention, arthralgia, and modest glucose changes. Active malignancy is a labeled contraindication. The safety record, cited. What the trials and reviews reported: injection-site reactions, growth-hormone-class effects, glucose monitoring, and the malignancy contraindication. Research findings, not medical advice. ## The short version Most reported tesamorelin side effects are the kind you would expect from a daily injection that raises growth hormone: redness or irritation where the needle goes, some fluid retention, joint aches, and small shifts in blood sugar [15]. Because the drug raises IGF-1 (a growth signal), people with an active cancer were told not to use it — that is a labeled contraindication [4]. Over a year of trials in HIV patients, there was no serious safety alarm, but long-term safety outside that group is not well studied [2][13]. This page summarizes the published safety record. ## The commonly reported effects Reported side effects center on injection-site reactions and growth-hormone-class effects such as fluid retention and arthralgia (joint pain) [15]. A 2026 sports-medicine review grouped tesamorelin among growth-hormone-axis secretagogues with uncertain safety profiles, alongside product-quality concerns for non-pharmaceutical material [15]. Across the 52-week HIV program, glucose changes were not clinically significant, and the 2026 meta-analysis of five RCTs reported no serious adverse events [2][13]. These effects trace directly to the mechanism: by raising endogenous GH and IGF-1, tesamorelin produces the fluid-shift and joint effects characteristic of growth-hormone signaling [4]. Notably, the metabolic picture in the trials was not uniformly a cost: inflammatory-marker work in the HIV population found tesamorelin reduced tissue plasminogen activator antigen and modestly increased adiponectin, with the changes tracking the degree of visceral-fat reduction [9], and a later analysis reported the drug improved fat quality — raising visceral- and subcutaneous-fat density on CT — independent of changes in fat amount [10]. Those are favorable signals reported alongside the side-effect record, not a contradiction of it. ## Blood sugar and glucose monitoring Growth-hormone-axis stimulation can modestly perturb glucose, so monitoring is reasonable in people with dysglycemia. The data, however, are reassuring within the studied populations. In 13 healthy men, 2 mg/day did not significantly affect fasting glucose (P=0.93) or insulin-stimulated glucose uptake (P=0.61) [4]. Over the 52-week HIV program, glucose changes were not clinically significant [2], and the pooled Phase 3 analysis found no clinically meaningful glucose changes [7]. A dedicated type-2-diabetes safety trial found no significant change in HbA1c. ## IGF-1, malignancy, and the labeled contraindication Raising IGF-1 is central to how tesamorelin works — IGF-1 rose 81% in the pivotal trial and by 181 ug/L in healthy men [1][4]. Because IGF-1 is a growth factor, active malignancy is a labeled contraindication for the approved product [4]. Trials showed no excess malignancy signal over 52 weeks, but long-term oncologic-safety data remain limited [2]. This is the central safety tension of the GHRH-analogue class: the same IGF-1 elevation that drives the benefit is the reason oncologic caution is built into the label. ## Mixed cognitive findings and what they imply Outside the fat and metabolic endpoints, the cognitive signal is genuinely mixed — a point the corpus flags rather than papers over. A non-HIV aging trial reported an executive-function benefit, but a separate HIV cognition trial did not show significant neurocognitive improvement over standard care. The honest reading is that cognitive effects are not established, and any cognitive use would be off-label and investigational [14]. This matters for a safety page because it is exactly the kind of secondary claim that gets oversold: the visceral-fat result is robust within HIV; the cognitive result is not. ## Who the studies suggest should avoid it, and scope limits Active malignancy is the clearest labeled contraindication, because the drug stimulates endogenous GH and raises serum IGF-1 [4]. Caution is also reasonable in individuals with prediabetes or dysglycemia given possible modest glucose perturbation [7]. Two scope limits matter for interpreting the safety record: the pivotal efficacy and safety trials were conducted in HIV-positive adults on antiretroviral therapy, so generalizability beyond that population is not established by large RCTs [14]; and visceral fat reaccumulates within weeks of discontinuation, so any studied benefit was contingent on continued dosing [2]. A predictor analysis also found that not everyone responded equally — baseline metabolic syndrome and higher triglycerides predicted a larger visceral-fat response, with no reliable predictor identifiable at 3 months [11]. Tesamorelin is also prohibited in sport under the WADA Prohibited List (category S2), in- and out-of-competition. Finally, research-grade material sold for laboratory use is not the approved finished product and carries no purity or potency oversight, a recurring caution in recent peptide reviews [15]. The full [references and citations](/references) document each safety finding. --- Tesamorelin read down to its numbers — one GHRH(1-44) analogue, the visceral-fat and IGF-1 figures left standing alone against the studies that measured them, and the approved-for-HIV-lipodystrophy line drawn exactly where the off-label field begins; an editorial reference plate, not a clinic, a vendor, or a prescription.